Sphera Funds Management LTD. bought a new stake in shares of Ovid Therapeutc (NASDAQ:OVID) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 305,674 shares of the company’s stock, valued at approximately $3,042,000. Sphera Funds Management LTD. owned 1.24% of Ovid Therapeutc as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Schwab Charles Investment Management Inc. bought a new position in Ovid Therapeutc during the second quarter valued at $153,000. Alps Advisors Inc. bought a new position in Ovid Therapeutc during the second quarter valued at $233,000. Bank of New York Mellon Corp bought a new position in Ovid Therapeutc during the second quarter valued at $135,000. Jennison Associates LLC bought a new position in Ovid Therapeutc during the second quarter valued at $6,739,000. Finally, Victory Capital Management Inc. bought a new position in Ovid Therapeutc during the second quarter valued at $1,374,000. 32.44% of the stock is owned by institutional investors.

Ovid Therapeutc (OVID) traded down 9.66% during trading on Friday, reaching $8.51. 43,605 shares of the company’s stock traded hands. The firm’s market capitalization is $209.35 million. The company has a 50-day moving average price of $7.85 and a 200 day moving average price of $10.50. Ovid Therapeutc has a one year low of $5.28 and a one year high of $15.93.

Ovid Therapeutc (NASDAQ:OVID) last released its earnings results on Thursday, August 10th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.09. On average, analysts anticipate that Ovid Therapeutc will post ($3.88) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Sphera Funds Management LTD. Buys Shares of 305,674 Ovid Therapeutc (OVID)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/sphera-funds-management-ltd-buys-shares-of-305674-ovid-therapeutc-ovid/1538182.html.

OVID has been the subject of several research analyst reports. Cowen and Company initiated coverage on shares of Ovid Therapeutc in a research note on Tuesday, May 30th. They set an “outperform” rating for the company. JMP Securities initiated coverage on shares of Ovid Therapeutc in a research note on Tuesday, May 30th. They set an “outperform” rating and a $26.00 target price for the company. William Blair initiated coverage on shares of Ovid Therapeutc in a research note on Tuesday, May 30th. They set an “outperform” rating for the company. Citigroup Inc. initiated coverage on shares of Ovid Therapeutc in a research note on Tuesday, May 30th. They set a “buy” rating and a $21.00 target price for the company. Finally, Zacks Investment Research cut shares of Ovid Therapeutc from a “hold” rating to a “sell” rating in a research note on Wednesday, August 16th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $23.50.

In other Ovid Therapeutc news, CEO Jeremy M. Levin bought 15,334 shares of the company’s stock in a transaction dated Friday, August 25th. The stock was acquired at an average price of $7.15 per share, with a total value of $109,638.10. Following the completion of the acquisition, the chief executive officer now directly owns 4,601,529 shares of the company’s stock, valued at $32,900,932.35. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Ovid Therapeutc Company Profile

Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.

Want to see what other hedge funds are holding OVID? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ovid Therapeutc (NASDAQ:OVID).

Institutional Ownership by Quarter for Ovid Therapeutc (NASDAQ:OVID)

Receive News & Ratings for Ovid Therapeutc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutc and related companies with Analyst Ratings Network's FREE daily email newsletter.